OraSure Technologies Inc (OSUR) FinancialsOSURFinancialOraSure Technologies Inc

OraSure Technologies Inc (OSUR) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Net product and services revenues - COVID-19, accounting for 46.6% of total sales, equivalent to $13.02M. Other significant revenue streams include Net product and services revenues - HIV and Net product and service revenues -Molecular Products. Understanding this composition is critical for investors evaluating how OSUR navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, OraSure Technologies Inc maintains a gross margin of 43.46%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -55.98%, while the net margin is 20.40%. These profitability ratios, combined with a Return on Equity (ROE) of -14.07%, provide a clear picture of how effectively OSUR converts its operational activities into shareholder value.

In the context of the broader market, OSUR competes directly with industry leaders such as ELMD and LAB. With a market capitalization of $254.49M, it holds a significant position in the sector. When comparing efficiency, OSUR's gross margin of 43.46% stands against ELMD's 78.71% and LAB's 52.40%. Such benchmarking helps identify whether OraSure Technologies Inc is trading at a premium or discount relative to its financial performance.

OraSure's revenue for Q2 2026 was reported at 30.6 million, reflecting a 9.7% sequential increase, but the company has faced substantial net losses, with a net income of -22.4 million in Q1 2026 and a negative EPS of -0.23 reported in the last earnings call.